Anakinra added to usual care for inflammatory dilated cardiomyopathy
Tests anakinra on heart pumping strength in adults with inflammatory dilated cardiomyopathy.
Key facts
- Who runs it
- Ospedale San Raffaele S.r.l.
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Registry title
- Targeted therapy with anakinra for dilated cardiomyopathy: phase IIa randomized double blind monocentric clinical trial to evaluate the efficacy and safety of anakinra plus standard of care vs standard of care alone in the treatment of dilated cardiomyopathy.
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 24 people, planned
- Started
- 25 May 2023
- Planned end
- 31 Dec 2025
- Type of study
- Interventional
- Record updated
- 16 October 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with dilated cardiomyopathy (an enlarged, weak heart muscle) with signs of heart inflammation. Their heart failure has not improved despite at least 3 months of usual treatment.
- Age
- 18 Years to 75 years
- Sex
- All sexes can join.
- Disease stage
- Dilated cardiomyopathy with LVEF<50% (heart pumping strength) on heart ultrasound. Heart failure symptoms and LVEF have not improved or have worsened despite at least 3 months of optimal therapy. People with coronary artery disease cannot join.
- Earlier treatment
- At least 3 months of optimal heart failure therapy. No prednisone >10 mg daily or immune-suppressing drugs within 3 months before joining. No biological anti-cytokine treatment within 5 half-lives of the drug.
- Biomarker or test result
- Raised high-sensitive troponin T (hs-TnT), and/or signs of current or past heart inflammation on cardiac MRI within 6 months. For the randomized part, CD3+ >7/mm2 cells on a heart tissue sample (EMB).
Main reasons for not taking part
- Genetic dilated cardiomyopathy, or heart damage from valve disease, toxins, alcohol or drugs
- Active, chronic or recurring infections, including tuberculosis, HIV, hepatitis B or hepatitis C
- Pregnancy or breastfeeding
- Current immune-suppressing medicines, or cancer in the previous 5 years (with some exceptions)
- Severe liver problems (Child-Pugh Class C) or kidney failure with eGFR <30 ml/min
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- Age: 18 Years to 75 years
- Diagnosis of DCM according to current guidelines
- Symptoms of HF not improved or worsened despite at least 3 months of optimal therapy
- LVEF<50% at echocardiography (TTE), not improved or worsened despite at least 3 months of optimal therapy
- Increased high-sensitive troponin T (hs-TnT), and/or findings suggestive for actual or prior myocardial inflammation at cardiac MRI (within 6 months)
- Absence of coronary artery disease (coronary artery stenosis > 50% at angiography or coronary CT Scan, acceptable if performed during the last 12 months)
- Ability to sign an informed consent
- Presence of CD3+ >7/mm2 cells on EMB, in addiction to all the aformentioned inclusion criteria, will be needed exclusively to be enrollend in the Phase IIa Randomized Double Blind monocentric Clinical Trial
Who cannot take part
- Any concomitant immune-suppressive medications (i.e. azathioprine, methotrexate, cyclosporine, mycophenolate, cyclophosphamide, rituximab, tacrolimus)
- Therapy with prednisone >10 mg daily and/or any immuno-suppressive agents within 3 months before the enrolment
- Congenital and/or acquired valvular disease or any other heart disease that could justify the severity of cardiac dysfunction; Major surgery within 2 weeks prior to randomization, or unhealed operation wounds
- Any other concomitant or previous biological anti-cytokine treatment administered within 5 -half lives of the specific drug
- Hepatic impairment = Child-Pugh Class C
- Contra-indication to ANAKINRA (known hypersensitivity to the active substance or to any of the excipients or to Escherichia coli-derived proteins)
- Any comorbidity limiting survival or conditions predicting inability to complete the study
- Clinical suspicion or proven underlying active, chronic or recurrent bacterial, fungal or viral infections, including tuberculosis, or HIV infection or epatitis B virus (HBV) or hepatitis C virus (HCV) infection, Lyme disease, Chagas disease or any other bacterial/fungeal/protozoal disease possibly responsible for DCM
- Endocrine, infiltrative (Cushing’s disease, acromegaly not clinically controlled hypo/hyperthyroidism, pheochromocytoma) or neuromuscular diseases (Dystrophinopathies [Duchenne/Becker muscular dystrophy/X-linked DCM], Limb-girdle muscular dystrophies, Facioscapulohumeral muscular dystrophy, Emery-Dreifuss muscular dystrophy, Friedreich’s ataxia, Myotonic dystrophy)
- History of malignancy in the previous 5 years. Exceptions are basal cell skin cancer, carcinoma-in-situ of the cervix or low-risk prostate cancer after curative therapy
- Contraindications to PET/MRI (i.e. gadolinium hypersensitivity, renal failure, claustrophobia, pacemaker or ICD device, blood glucose>12.5 mmol/L)
- Renal failure as defined by estimated glomerular filtration rate (eGFR) <30 ml/min, according to Cockcroft-Gault
- Genetic DCM
- Mechanical ventilation circulatory assistance
- Pregnancy, breastfeeding. Female patients of childbearing potential may participate if adequate contraception is used during the study. (For the purposes of this trial, women of childbearing potential are defined as “All female subjects after puberty unless they are post-menopausal for at least 2 years or are surgically sterile.”)
- Presence of neutropenia < 1,5.109/L), or thrombocytopenia < 50.000/mm3
- Toxin abuse/exposure (Alcohol, amphetamines, cocaine, anthracyclines [e.g., doxycycline], trastuzumab, clozapine, chloroquine, carbon monoxide, cobalt, lead, mercury
- Contraindications to EMB
This trial is currently available in Italy.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the efficacy of IL-1 therapeutic blockade with Anakinra in improving Left Ventricular Ejection Fraction (LVEF) assessed by Trans Thoracic Echocardiograhy (TTE) at 4 weeks.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Deciphering IL-1 mediated inflammation for the targeted treatment of dilated cardiomyopathy.
- Plain-language title
- Anakinra added to usual care for inflammatory dilated cardiomyopathyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 16 October 2024